Compare MLSS & CTXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MLSS | CTXR |
|---|---|---|
| Founded | 1989 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.1M | 18.9M |
| IPO Year | 1996 | 2010 |
| Metric | MLSS | CTXR |
|---|---|---|
| Price | $0.33 | $0.69 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | $1.00 | ★ $6.00 |
| AVG Volume (30 Days) | ★ 1.3M | 759.8K |
| Earning Date | 05-14-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 43.38 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $8,973,982.00 | N/A |
| Revenue This Year | $12.64 | N/A |
| Revenue Next Year | $8.99 | $147.57 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 3.99 | N/A |
| 52 Week Low | $0.22 | $0.57 |
| 52 Week High | $1.07 | $2.38 |
| Indicator | MLSS | CTXR |
|---|---|---|
| Relative Strength Index (RSI) | 60.23 | 43.05 |
| Support Level | $0.24 | $0.68 |
| Resistance Level | $0.40 | $0.99 |
| Average True Range (ATR) | 0.03 | 0.07 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 89.50 | 26.76 |
Milestone Scientific Inc develops and commercializes proprietary computer-controlled drug delivery systems designed to enhance the safety, precision, and patient experience associated with subcutaneous injections and fluid aspiration procedures. The company's core technology platform, Dynamic Pressure Sensing (DPS) Technology, controls flow rate and measures pressure at the needle tip in real time. DPS Technology is incorporated into both the company's dental and medical products and supports clinical applications, including local anesthesia delivery, epidural space identification in regional anesthesia procedures, and intra-articular joint injections. It operates in two segments: Dental, which markets and sells its dental products, and Medical, markets and sells its medical products.
Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.